Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone801-253-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$882.75 million
Profitability
Miscellaneous
Employees5,783
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Merit Medical Systems (NASDAQ:MMSI) Frequently Asked Questions
What is Merit Medical Systems' stock symbol?
Merit Medical Systems trades on the NASDAQ under the ticker symbol "MMSI."
How were Merit Medical Systems' earnings last quarter?
Merit Medical Systems, Inc. (NASDAQ:MMSI) posted its quarterly earnings results on Thursday, July, 25th. The medical instruments supplier reported $0.42 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.50 by $0.08. The medical instruments supplier earned $255.50 million during the quarter, compared to analysts' expectations of $258.58 million. Merit Medical Systems had a return on equity of 10.40% and a net margin of 4.10%. The business's quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. View Merit Medical Systems' Earnings History.
When is Merit Medical Systems' next earnings date?
What guidance has Merit Medical Systems issued on next quarter's earnings?
Merit Medical Systems issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $1.74-1.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.01. The company issued revenue guidance of $1.007-1.029 billion, compared to the consensus revenue estimate of $1.02 billion.
What price target have analysts set for MMSI?
8 brokerages have issued 1-year price objectives for Merit Medical Systems' shares. Their forecasts range from $37.00 to $74.00. On average, they anticipate Merit Medical Systems' stock price to reach $54.5714 in the next year. This suggests a possible upside of 82.5% from the stock's current price. View Analyst Price Targets for Merit Medical Systems.
What is the consensus analysts' recommendation for Merit Medical Systems?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merit Medical Systems in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merit Medical Systems.
What are Wall Street analysts saying about Merit Medical Systems stock?
Here are some recent quotes from research analysts about Merit Medical Systems stock:
- 1. Barrington Research analysts commented, "We would gently suggest that with shares down over 55% over the past few months that perhaps the miss, the guidedown, the “drama”, and even a riskier near‐term growth profile might mostly be “in the stock” at this point. We simply think the risk/reward now favors investment – even if Q3 comes in soft. We will try to make our argument in brief below." (9/12/2019)
- 2. According to Zacks Investment Research, "Shares of Merit Medical outperformed the industry in a year’s time. Significant expansion in adjusted gross margins in recent times buoy optimism in the stock. Robust Cardiovascular unit also encourages. Management is optimistic about Merit Medical’s Becton Dickinson deal that is set for completion at the end of 2019. Cianna Medical and Vascular Insights buyouts continue to contribute to results. Management is optimistic about several new products that are slated for introduction in the second quarter of 2019. However, escalating operating expenses remains a concern for the company. Headwinds like stiff competition and higher consolidation in the healthcare industry add to the woes. Sluggishness in the Custom kits and procedure trays and Embolization devices units is also concern. The stock is overvalued at the moment." (7/1/2019)
- 3. Needham & Company LLC analysts commented, "MMSI’s 1Q19 revenue and EPS beat consensus (due to a lower than expected tax rate). Management reiterated its 2019 revenue and EPS guidance. Organic revenue growth slowed from 4Q18 despite an easier comp. Gross margin expansion was partially offset by higher SG&A but MMSI still delivered 60 bps of Y/Y operating margin improvement. We still believe there are multiple sources of upside to revenue (e.g. BD products are organic, Cianna SCOUT would be incremental) and EPS guidance (e.g. continued margin improvement) and we reiterate our Buy rating." (4/25/2019)
Has Merit Medical Systems been receiving favorable news coverage?
Press coverage about MMSI stock has been trending negative on Tuesday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Merit Medical Systems earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Merit Medical Systems.
Who are some of Merit Medical Systems' key competitors?
Some companies that are related to Merit Medical Systems include Penumbra (PEN), Integra Lifesciences (IART), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK) and Luminex (LMNX).
What other stocks do shareholders of Merit Medical Systems own?
Who are Merit Medical Systems' key executives?
Merit Medical Systems' management team includes the folowing people:
- Mr. Fred P. Lampropoulos, Chairman, CEO & Pres (Age 69)
- Mr. Ronald A. Frost, Chief Operating Officer (Age 57)
- Mr. Brian G. Lloyd, Chief Legal Officer & Corp. Sec. (Age 58)
- Mr. Joseph C. Wright, Pres of International Division (Age 49)
- Mr. Raul Parra Jr., CPA, CFO & Treasurer
Who are Merit Medical Systems' major shareholders?
Merit Medical Systems' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.58%), BlackRock Inc. (15.53%), Vanguard Group Inc. (10.06%), Eagle Asset Management Inc. (3.35%), Invesco Ltd. (1.77%) and Jennison Associates LLC (1.70%). Company insiders that own Merit Medical Systems stock include F Ann Millner, Franklin J Miller, Fred P Lampropoulos, Joseph Wright, Justin J Lampropoulos, Kent W Stanger, Michael E Stillabower, Nolan E Karras, Raul Jr Parra and Ronald Frost. View Institutional Ownership Trends for Merit Medical Systems.
Which institutional investors are selling Merit Medical Systems stock?
MMSI stock was sold by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Perceptive Advisors LLC, SG Capital Management LLC, Mackenzie Financial Corp, Mackenzie Financial Corp, Russell Investments Group Ltd., Axiom International Investors LLC DE and Eagle Boston Investment Management Inc.. Company insiders that have sold Merit Medical Systems company stock in the last year include F Ann Millner, Franklin J Miller, Fred P Lampropoulos, Justin J Lampropoulos, Kent W Stanger, Michael E Stillabower, Nolan E Karras, Raul Jr Parra and Ronald Frost. View Insider Buying and Selling for Merit Medical Systems.
Which institutional investors are buying Merit Medical Systems stock?
MMSI stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, BlackRock Inc., BlackRock Inc., Invesco Ltd., Nuveen Asset Management LLC, Morgan Stanley, Fiera Capital Corp and Landscape Capital Management L.L.C.. View Insider Buying and Selling for Merit Medical Systems.
How do I buy shares of Merit Medical Systems?
Shares of MMSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Merit Medical Systems' stock price today?
One share of MMSI stock can currently be purchased for approximately $29.91.
How big of a company is Merit Medical Systems?
Merit Medical Systems has a market capitalization of $1.65 billion and generates $882.75 million in revenue each year. The medical instruments supplier earns $42.02 million in net income (profit) each year or $1.69 on an earnings per share basis. Merit Medical Systems employs 5,783 workers across the globe.View Additional Information About Merit Medical Systems.
What is Merit Medical Systems' official website?
How can I contact Merit Medical Systems?
Merit Medical Systems' mailing address is 1600 WEST MERIT PARK WAY, SOUTH JORDAN UT, 84095. The medical instruments supplier can be reached via phone at 801-253-1600 or via email at [email protected]
MarketBeat Community Rating for Merit Medical Systems (NASDAQ MMSI)
MarketBeat's community ratings are surveys of what our community members think about Merit Medical Systems and other stocks. Vote "Outperform" if you believe MMSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MMSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
